ClinicalTrials.gg
Not yet recruitingNCT07843706Updated Oct 26, 2026

Empowering Pain Psychology Access and Collaboration (EPPAC) to Improve Treatment Engagement Among Medicaid-insured Adults With Chronic Low Back Pain

An interventional study of Empowering Pain Psychology Access and Collaboration (EPPAC) and Usual Care Pain Psychology Evaluation in Chronic Low Back Pain (CLBP), sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 26, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Low Back Pain by Johns Hopkins University — 3 open to participants now, 3 under way, none of them phase 3. Low Back Pain · Johns Hopkins University.

Planned enrollment
12th of 16
70 · median 117
Started
2026
the only one that year
No phase
12 of 17
3 open now
Registered
17th of 17
by date

Among the 17 studies in Low Back Pain by Johns Hopkins University, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 17th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

3 of the 17 studies in Low Back Pain by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Low Back Pain by Johns Hopkins University, or all of them as a file.
02

Study summary

Chronic low back pain (cLBP) is a leading cause of disability, with socioeconomically disadvantaged populations experiencing worse outcomes and lower rates of treatment initiation for evidence-based pain psychology services. Participant engagement strategies such as shared decision-making (SDM) and motivational interviewing (MI) have shown promise in improving treatment uptake, but no study has examined whether integrating these approaches into a pain psychology evaluation can improve engagement among socioeconomically disadvantaged participants or offered participants a structured choice between cognitive behavioral therapy (CBT) and emotional awareness and expression therapy (EAET), presented to participants as Pain and Emotion Reprocessing Therapy (PERT). The Empowering Pain Psychology Access and Collaboration (EPPAC) intervention, a brief, psychologist-led engagement strategy combining SDM and MI within a standard pain psychology evaluation, was developed to address this gap.

Read the detailed description

Chronic low back pain (cLBP) is among the leading causes of disability worldwide, affecting approximately 12.8 million adults in the United States. Individuals with low socioeconomic status (SES) are disproportionately affected, with roughly twice the rate of developing cLBP compared with higher-SES populations. The investigator's prior work has shown that socioeconomically disadvantaged adults with cLBP report worse pain-related outcomes than more advantaged counterparts, underscoring the need for effective and accessible treatments in this population.

Clinical practice guidelines recommend nonpharmacological approaches, including pain psychology, as first-line treatments for cLBP. Among the most established pain psychology treatments is cognitive behavioral therapy (CBT), which targets maladaptive patterns of thinking and behavior that contribute to pain, disability, and distress. A growing evidence base also supports emotional awareness and expression therapy (EAET), presented to participants in REACH as Pain and Emotion Reprocessing Therapy (PERT). EAET is grounded in contemporary pain neuroscience and addresses emotional experiences, stress, and interpersonal processes that may contribute to chronic pain.

Despite the availability of these treatments, a substantial proportion of participants referred for pain psychology do not initiate treatment, with reported initiation rates ranging from 24% to 73%. Preliminary findings from the OPTIMIZE trial, a pragmatic comparative effectiveness study of nonpharmacological treatments for cLBP conducted across three US health systems, indicate that only 59% of participants randomized to CBT initiated treatment, with socioeconomic factors such as neighborhood deprivation emerging as significant predictors of non-initiation. These findings suggest that socioeconomically disadvantaged participants face distinct barriers to engaging with psychological treatments for pain, and that simply offering effective treatments is insufficient if participants do not start treatments.

Participant engagement strategies have shown promise in improving treatment uptake. Shared decision-making (SDM) supports informed choices by presenting treatment options alongside benefits and trade-offs in a structured, collaborative conversation. Motivational interviewing (MI) supports motivation by exploring ambivalence and strengthening commitment in a non-confrontational manner. A prior trial by the investigator's team demonstrated that a single-session MI intervention delivered during a clinical encounter increased participation in physical therapy, reduced disability, and improved health outcomes among adults undergoing surgery for degenerative lumbar spinal stenosis. More recently, the Equity Using Interventions for Pain and Depression (EQUIPD) pilot trial demonstrated that coaching paired with a decision aid to facilitate SDM about nonpharmacological pain treatments was feasible and showed improvements in shared decision-making, participant engagement, and therapeutic alliance among Black participants with chronic musculoskeletal pain. However, no study has examined whether integrating SDM and MI into a pain psychology evaluation can improve treatment initiation among socioeconomically disadvantaged participants, nor has any study offered participants a structured choice between CBT and EAET.

To address this gap, the Empowering Pain Psychology Access and Collaboration (EPPAC) intervention, a brief, psychologist-led engagement strategy designed to be embedded within a standard pain psychology evaluation, was developed. EPPAC combines MI techniques with a structured SDM framework to help participants understand how psychology relates to pain, explore whether treatment fits the participant's situation, and choose between CBT and EAET based on the participant's values and preferences. In participant-facing REACH materials, EAET is presented as Pain and Emotion Reprocessing Therapy (PERT). The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of EPPAC compared with usual care among Medicaid-insured adults with cLBP in a pilot randomized controlled trial.

03

Conditions studied

  • Chronic Low Back Pain (CLBP)

Browse trials for

Keywords

  • chronic low back pain
  • pain psychology
  • shared decision-making
  • motivational interviewing
  • participant engagement
  • health disparities
  • Medicaid
  • pilot randomized controlled trial
  • cognitive behavioral therapy
  • emotional awareness and expression therapy
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic low back pain lasting at least 3 months and present at least half the days in the past 6 months, with an Oswestry Disability Index (ODI) score of at least 24%
  • Medicaid insurance as primary or secondary coverage documented in the medical record, including eligible dual Medicare-Medicaid coverage
  • Able to complete study procedures in English
  • Able to participate in the telehealth clinical workflow and complete online questionnaires, with telephone assistance when needed

Exclusion criteria

Exclusion Criteria:

  • Specific spinal pathology or medical condition requiring immediate intervention that makes study participation inappropriate
  • Currently receiving psychological treatment specifically for chronic pain at the time of screening
  • Lumbar spine surgery within the past 6 months
  • Severe psychiatric, cognitive, or substance-related condition that interferes with safe participation or meaningful consent
  • Enrollment in another interventional study for chronic low back pain that could confound study outcomes
  • Current cancer other than skin cancer
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Empowering Pain Psychology Access and Collaboration (EPPAC)

    Participants receive the standard pain psychology evaluation followed by the structured EPPAC engagement and shared decision-making process during the same scheduled telehealth appointment. EPPAC helps participants decide whether pain psychology fits their treatment plan and, if treatment is selected, choose between cognitive behavioral therapy (CBT) and emotional awareness and expression therapy (EAET), presented to participants as Pain and Emotion Reprocessing Therapy (PERT). Subsequent CBT or EAET/PERT treatment is routine clinical care and is available in both study arms.

    Behavioral: Empowering Pain Psychology Access and Collaboration (EPPAC)

  • Active comparator
    Usual Care

    Participants receive the standard pain psychology evaluation and the clinic's usual discussion of treatment recommendations and available options, without the EPPAC-specific structured elements. CBT and EAET, presented to participants as PERT, remain available as clinically appropriate. Subsequent treatment is routine clinical care.

    Behavioral: Usual Care Pain Psychology Evaluation

Interventions

  • BehavioralEmpowering Pain Psychology Access and Collaboration (EPPAC)

    EPPAC is a brief, psychologist-led engagement strategy embedded within a standard pain psychology evaluation. It combines motivational interviewing and shared decision-making, structured pain education, a patient decision aid, two decision points, balanced discussion of CBT and EAET (presented to participants as PERT), and next-step planning to support informed engagement in pain psychology care.

  • BehavioralUsual Care Pain Psychology Evaluation

    Usual care consists of the clinic's standard pain psychology evaluation and usual discussion of clinical recommendations and treatment options. It does not include the EPPAC-specific decision aid, standardized EPPAC pain education, exact Decision Point 1 question, or EPPAC next-steps probe. CBT and EAET, presented to participants as PERT, are downstream clinical treatment options available in both study arms.

06

What researchers measure

Primary outcomes

  1. Percentage of participant and provider Acceptability of Intervention Measure (AIM) responses with a mean score of 4 or greater

    The AIM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater acceptability. Participant and provider responses will be summarized separately. For this pilot, the prespecified study-defined acceptability benchmark is at least 70% of participant responses and at least 70% of provider responses with a mean AIM score of 4 or greater.

    Time frame: Immediately following the initial evaluation appointment

  2. Percentage of participant and provider Intervention Appropriateness Measure (IAM) responses with a mean score of 4 or greater

    The IAM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater perceived appropriateness. The percentage of responses with a mean score of 4 or greater will be reported separately for participants and providers and interpreted descriptively; no pass/fail appropriateness threshold is prespecified.

    Time frame: Immediately following the initial evaluation appointment

  3. Proportion of EPPAC evaluations in which the required core EPPAC components were delivered as intended

    Fidelity will be assessed using structured provider-completed documentation in Epic indicating completion of the core EPPAC stages and intervention components. For this pilot, the prespecified study-defined feasibility benchmark is delivery of the required EPPAC components in at least 70% of EPPAC evaluation visits. Sessions will not be recorded or independently coded for fidelity.

    Time frame: Immediately following the initial evaluation appointment

  4. Percentage of participant and provider Feasibility of Intervention Measure (FIM) responses with a mean score of 4 or greater

    The FIM is a 4-item measure scored on a 5-point Likert scale (1 = Completely disagree to 5 = Completely agree). A respondent-level mean score is calculated across the four items, with higher scores indicating greater perceived feasibility. The percentage of responses with a mean score of 4 or greater will be reported separately for participants and providers and interpreted descriptively; the study's prespecified feasibility benchmark is based on EPPAC delivery fidelity rather than an FIM cutoff.

    Time frame: Immediately following the initial evaluation appointment

Secondary outcomes

  1. Percentage of randomized participants initiating pain psychology treatment by 12 weeks

    Treatment initiation is defined as attendance at least one cognitive behavioral therapy (CBT) or emotional awareness and expression therapy (EAET; presented to participants as PERT) treatment session documented in the electronic medical record (EMR) within 12 weeks. The denominator is all randomized participants, consistent with the intent-to-treat approach.

    Time frame: 12 weeks

  2. Total number of treatment sessions attended (out of 8 sessions)

    Total number of treatment sessions attended will be determined using the EMR.

    Time frame: 12 weeks

  3. Participant's choice of treatment

    Participant treatment decision at the end of the evaluation workflow, categorized as cognitive behavioral therapy (CBT), emotional awareness and expression therapy (EAET; presented to participants as PERT), or no treatment selected, assessed by randomized arm.

    Time frame: Immediately following the initial evaluation appointment

  4. Percentage of treatment initiators who discontinue treatment before completing 6 sessions

    Among participants who initiate pain psychology treatment by attending at least one CBT or EAET/PERT session, treatment dropout is defined as discontinuing before completion of 6 treatment sessions within the 12-week treatment-engagement period. Treatment attendance will be determined using the EMR.

    Time frame: 12 weeks

  5. The frequency of participants who stated a preference for Cognitive Behavioral Therapy (CBT), Emotional Awareness and Expression Therapy (EAET; presented to participants as PERT), or were unsure.

    Participants' stated treatment preference will be assessed using a single item completed prior to completion of the decisional conflict measure.

    Time frame: Immediately following the initial evaluation appointment

  6. Percentage of participants with decisional conflict on the Sure of myself, Understand information, Risk-benefit ratio, Encouragement (SURE) test

    The SURE test is a 4-item binary screening measure derived from the Decisional Conflict Scale. Each item is scored 0 or 1, yielding a total score from 0 to 4. A score of 4 (better) indicates no decisional conflict; scores of 0 to 3 indicate decisional conflict.

    Time frame: Immediately following the initial evaluation appointment

  7. CollaboRATE shared decision-making score

    CollaboRATE is a 3-item participant-reported measure of the shared decision-making process. Each item is scored from 0 (no effort was made) to 4 (every effort was made), yielding a total score from 0 to 12, with higher scores indicating greater shared decision-making. A top score is defined as the highest response on all three items and may also be reported as the proportion of participants achieving a top score.

    Time frame: Immediately following the initial evaluation appointment

  8. Participant openness to future engagement, assessed by arm and by treatment initiation status.

    Participant openness to future engagement, assessed with an investigator-developed single item: "If my situation changes in the future, I would consider working with a psychologist for my pain." This item is rated on a 5-point agreement scale with higher scores indicating greater levels of openness to future engagement.

    Time frame: Immediately following the initial evaluation appointment

  9. Pain Self-Efficacy Questionnaire-Two-Item Short Form (PSEQ-2)

    The Pain Self-Efficacy Questionnaire 2-item short form (PSEQ-2) assesses confidence in performing activities despite pain. Total scores range from 0 to 12, with higher scores indicating greater pain self-efficacy.

    Time frame: Baseline, 12 weeks, and 24 weeks

  10. Oswestry Disability Index (ODI)

    The Oswestry Disability Index is a 10-item measure of low back pain-related disability across pain intensity and daily activities. Each item is scored from 0 to 5. The item scores are summed and converted to a percentage disability score ranging from 0% to 100%, with higher scores indicating greater disability.

    Time frame: Screening, 12 weeks, and 24 weeks

  11. Patient-Reported Outcome Measurement Information System (PROMIS-29+2 Profile v2.1 (PROPr))

    The Patient-Reported Outcome Measurement Information System (PROMIS-29+2 Profile v2.1 \[PROPr\]) assesses 8 domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Pain Interference, and Cognitive Function-Abilities, in addition to a Pain Intensity item. The multi-item domains use 5-category response scales and are converted to standardized T-scores (mean = 50, standard deviation = 10); the Pain Intensity item is scored from 0 to 10. Higher T-scores indicate more of the construct being measured. For symptom domains such as Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, higher scores indicate worse symptoms; for Physical Function and Ability to Participate in Social Roles and Activities, higher scores indicate better functioning.

    Time frame: Baseline, 12 weeks, and 24 weeks

  12. University of Washington Concerns About Pain Scale (UW-CAP) 6-item short form))

    The University of Washington Concerns About Pain Scale 6-item short form (UW-CAP-6) assesses pain catastrophizing, described in the instrument as concerns about pain. Each item uses five response options coded from 1 to 5. The six item codes are summed only as an intermediate raw score (range 6 to 30) and then converted using the published concordance table to an item response theory (IRT)-based T-score. The T-score, rather than the raw sum, will be reported and analyzed. Higher T-scores indicate greater concerns about pain; the calibration metric has a mean of 50 and standard deviation of 10.

    Time frame: Baseline, 12 weeks, and 24 weeks

  13. Patient Global Impression of Change (PGIC)

    The Patient Global Impression of Change (PGIC) is a single-item participant-reported measure of overall change in activity limitations, symptoms, emotions, and quality of life related to the painful condition. Responses are rated on a 7-point scale from 1 = No change (or condition has gotten worse) to 7 = A great deal better, with higher scores indicating greater perceived improvement. Scores of 5, 6, and 7 correspond to moderately better, better, and a great deal better, respectively.

    Time frame: 12 weeks and 24 weeks

  14. The STarT Back Screening Tool (SBST)

    The STarT (Subgroups for Targeted Treatment) Back Screening Tool (SBST) was developed as a risk stratification tool for future persistent disabling low back pain. This tool is comprised of 9 items (scored 0 or 1 point). Scores range from 0 to 9. Participants with scores of 3 or lower may have a low risk for future persistent disabling low back pain and related activity limitations. Participants with scores of 4 or higher have an increased risk for these same outcomes. There is also a Psychosocial Distress Subscore that distinguishes between medium and high risk subgroups, based on the last five items of the tool. Participants with a Distress Subscore of 0-3 points are categorized as medium risk and those with a Distress Subscore of 4 or higher are considered high risk for persistent disabling back pain.

    Time frame: Baseline

07

Study locations

1 site
  • Johns Hopkins Rehabilitation Psychology Clinic
    Baltimore, Maryland 21205, United States
    • Fenan S Rass, Ph.D. · Contactfrassu1@jhmi.edu · 667-306-7983
    • Rachel V Aaron, Ph.D. · Contactraaron4@jhmi.edu · 667-306-7797
    • Fenan S Rassu, Ph.D. · Principal investigator
    • Rachel V Aaron, Ph.D. · Sub investigator
08

References and documents

Publications

  • Fritz, J., Rassu, F., Aaron, R., Minick, K., Brennan, G., Wegener, S. T., Thackeray, A., McLaughlin, K., & Skolasky, R. (2025, December 15). Factors Influencing Initiation of Evidence-Based Nonpharmacological Treatments for Chronic Low Back Pain within Health Systems. 18th Annual Conference on the Science of Dissemination and Implementation. https://academyhealth.confex.com/academyhealth/2025di/meetingapp.cgi/Paper/75964
  • Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1. PubMed 36327391 ↗
  • Williams ACC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD007407. doi: 10.1002/14651858.CD007407.pub4. PubMed 32794606 ↗
  • GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. PubMed 28919117 ↗
  • Skolasky RL, Maggard AM, Li D, Riley LH 3rd, Wegener ST. Health behavior change counseling in surgery for degenerative lumbar spinal stenosis. Part I: improvement in rehabilitation engagement and functional outcomes. Arch Phys Med Rehabil. 2015 Jul;96(7):1200-7. doi: 10.1016/j.apmr.2015.03.009. Epub 2015 Mar 28. PubMed 25827657 ↗
  • Skolasky RL, Wegener ST, Aaron RV, Ephraim P, Brennan G, Greene T, Lane E, Minick K, Hanley AW, Garland EL, Fritz JM. The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC Musculoskelet Disord. 2020 May 11;21(1):293. doi: 10.1186/s12891-020-03324-z. PubMed 32393216 ↗
  • Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PubMed 26991822 ↗
  • Rassu FS, McFadden M, Aaron RV, Wegener ST, Ephraim PL, Lane E, Brennan G, Minick KI, Fritz JM, Skolasky RL. The Relationship Between Neighborhood Deprivation and Perceived Changes for Pain-Related Experiences Among US Patients with Chronic Low Back Pain During the COVID-19 Pandemic. Pain Med. 2021 Nov 26;22(11):2550-2565. doi: 10.1093/pm/pnab179. PubMed 34181008 ↗
  • Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Denberg TD, Barry MJ, Boyd C, Chow RD, Fitterman N, Harris RP, Humphrey LL, Vijan S. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-530. doi: 10.7326/M16-2367. Epub 2017 Feb 14. PubMed 28192789 ↗
  • Putrik P, Ramiro S, Orueta JF, Keszei A, Alonso Moran E, Nuno Solinis R, Boonen A. Socio-economic inequalities in occurrence and health care costs in rheumatic and musculoskeletal diseases: results from a Spanish population-based study including 1.9 million persons. Clin Exp Rheumatol. 2018 Jul-Aug;36(4):589-594. Epub 2018 Jan 31. PubMed 29465359 ↗
  • Matthias MS, Burgess DJ, Daggy JK, Donnelly CE, Flores P, Fowler NR, Garabrant J, Henry N, Henry SG, Huffman M, Kavuri PJ, Ofner S, Perry C, Rand KL, Robles M, Salyers MP, Taylor SL, Hirsh AT. Equity Using Interventions for Pain and Depression (EQUIPD): A pilot randomized trial. J Pain. 2025 Apr;29:105353. doi: 10.1016/j.jpain.2025.105353. Epub 2025 Feb 25. PubMed 40010678 ↗
  • Lumley MA, Schubiner H. Psychological Therapy for Centralized Pain: An Integrative Assessment and Treatment Model. Psychosom Med. 2019 Feb/Mar;81(2):114-124. doi: 10.1097/PSY.0000000000000654. PubMed 30461545 ↗
  • Lawrence P, Fulbrook P, Somerset S, Schulz P. Motivational interviewing to enhance treatment attendance in mental health settings: A systematic review and meta-analysis. J Psychiatr Ment Health Nurs. 2017 Nov;24(9-10):699-718. doi: 10.1111/jpm.12420. Epub 2017 Sep 14. PubMed 28816412 ↗
  • Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 Jun 9;391(10137):2368-2383. doi: 10.1016/S0140-6736(18)30489-6. Epub 2018 Mar 21. PubMed 29573872 ↗
  • Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, Tomson D, Dodd C, Rollnick S, Edwards A, Barry M. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012 Oct;27(10):1361-7. doi: 10.1007/s11606-012-2077-6. Epub 2012 May 23. PubMed 22618581 ↗
  • Elwyn G, Dehlendorf C, Epstein RM, Marrin K, White J, Frosch DL. Shared decision making and motivational interviewing: achieving patient-centered care across the spectrum of health care problems. Ann Fam Med. 2014 May-Jun;12(3):270-5. doi: 10.1370/afm.1615. PubMed 24821899 ↗
  • Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014 Feb-Mar;69(2):153-66. doi: 10.1037/a0035747. PubMed 24547801 ↗
  • Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012 Mar 1;366(9):780-1. doi: 10.1056/NEJMp1109283. No abstract available. PubMed 22375967 ↗
  • Alperstein D, Sharpe L. The Efficacy of Motivational Interviewing in Adults With Chronic Pain: A Meta-Analysis and Systematic Review. J Pain. 2016 Apr;17(4):393-403. doi: 10.1016/j.jpain.2015.10.021. Epub 2015 Nov 27. PubMed 26639413 ↗

Individual participant data

Plan to share: Yes — De-identified data will be deposited in the Inter-university Consortium for Political and Social Research (ICPSR). The dataset will consist of: participant study identification number, treatment arm assignment, coarsened demographic variables (age range, sex, race and ethnicity, insurance type), responses to validated survey instruments at each assessment timepoint, session attendance counts, and treatment initiation and completion status. During the oral consent process, the study coordinator asks each participant whether the participant agrees to have their de-identified data deposited in a public research data repository. The response is recorded in REDCap at the time of consent. Participants who decline are enrolled and participate in all study activities without restriction; their records are flagged and excluded from the deposit.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified individual participant data and associated documentation will be made available through ICPSR after completion of the study, final data cleaning, and publication of the primary study findings, in accordance with NIH, Johns Hopkins University, and ICPSR requirements. Data will remain available according to ICPSR repository policies.

Access criteria: De-identified data will be shared through ICPSR in accordance with the repository's applicable access and data-use procedures. Only data from participants who agreed during the consent process to repository sharing will be included. Direct identifiers will not be shared.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartEst.
Nov 30, 2026was Oct 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Nov 30, 2026
moved 2 times, Oct 9, 2026 – Oct 26, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 3 updates
  1. Oct 26, 2026
    Start date Nov 2, 2026→Nov 30, 2026
  2. Oct 9, 2026
    Start date Oct 15, 2026→Nov 2, 2026
    + 1 other change: verification date
  3. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843706
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Fenan S Rassu, Ph.D.
Contact
frassu1@jhmi.edu
667-306-7983
Rachel V Aaron, Ph.D.
Contact
raaron4@jhmi.edu
667-306-7797
Fenan S Rassu, Ph.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion